About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Monday, October 2nd, 2017

The QualityStocks
Daily Stock List


MyDx, Inc. (MYDX)

Cabot Wealth, SmallCap Network, Promotion Stock Secrets, CFN Media Group, Cannabis Financial Network News, and Greenbackers reported on MyDx, Inc. (MYDX), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Orgenesis, Inc. is a fully-integrated cell therapy and contract development and manufacturing company. It has a novel therapeutic technology for the treatment of diabetes. The Company has expertise and unique experience in cell therapy development and manufacturing. OTCQB-listed, Orgenesis is based in Germantown, Maryland.

In addition, the Company has a fully-owned subsidiary contract manufacturing and development company -  MaSTherCell S.A. (Belgian subsidiary). This subsidiary’s dedication is to cell therapy for advanced medicinal products. MaSTherCell (a full-service contract development and manufacturing organization (CDMO)) specializes in the delivery of optimized process industrialization capacities to cell therapy organizations 

Furthermore, by way of its Israeli subsidiary, Orgenesis Ltd., Orgenesis is a pioneer in the development of technology designed to successfully reprogram human liver cells into glucose-responsive, fully functional, Insulin Producing Cells (IPCs). 

Orgenesis has a novel therapeutic approach in the treatment of diabetes through correcting malfunctioning organs with new functional tissues created from the patient’s own existing organs. The Company uses a molecular and cellular approach directed at transforming liver cells into functional insulin-producing cells as a treatment for diabetes. The new therapeutic approach is called Autologous Insulin Producing (AIP) cell transplantation.

Through its Israeli subsidiary, Orgenesis continues to advance its innovative cell-based therapy, the Autologous Insulin Producing (AIP) cells, into clinical development.  AIP cells use the technology of 'cellular transdifferentiation' to transform an autologous adult liver cell into a fully functional and physiologically glucose-responsive insulin-producing cell. 

Orgenesis has demonstrated promising results in in-vitro and in-vivo studies using human liver tissues. It designed an efficient and clear work-plan to start clinical testing soon, allowing it to launch Phase I clinical trials following Food and Drug Administration (FDA) guidelines followed by the launch of Phase II clinical trials within a year.

In 2016, Orgenesis entered into a number of strategic partnerships and joint venture (JV) agreements. It entered into a JV Agreement with CureCell; it is collaborating in the contract development and manufacturing of cell therapy products in Korea.

Orgenesis Ltd, its Israeli subsidiary, entered into a pharma Cooperation and Project Funding Agreement (CPFA) with KORIL and CureCell in 2016. KORIL will provide funding for a joint research and development project for the use of AIP cells for the treatment of diabetes.

Orgenesis also entered into a JV agreement with Atvio Biotech Ltd., an Israeli company. This agreement is to collaborate in the contract development and manufacturing of cell and virus therapy products in the field of regenerative medicine.

MyDx, Inc. (MYDX), closed Monday's trading session at $0.0044, down 6.38%, on 11,792,631 volume with 108 trades. The average volume for the last 60 days is 9,268,866 and the stock's 52-week low/high is $0.001/$0.085.

Identillect Technologies Corp. (IDTLF)

Stockhouse, OTC Markets, InvestorsHub, Investors Hangout, Investopedia, and Stock Orange reported on Identillect Technologies Corp. (IDTLF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Identillect Technologies Corp. is a top provider of SaaS (Software as a Service) email security. Its Delivery Trust™ email security technology platform allows individuals and businesses of all sizes a cost-effective way to create a more secure digital environment and protect against cyber security risks. Listed on the OTC Markets Group’s OTCQB,  Identillect Technologies is based in Irvine, California.

Delivery Trust™ is the industry’s simplest plug and play security solution. Delivery Trust™ is an award -winning, multi-platform plug-in that gives users complete control of their emails, for one low price.

It has a broad range of features. These include state of the art encryption technology, restricting email forwarding and printing, receipt confirmation, limiting time available to view, and retracting sent emails. Delivery Trust™ is available for iPhone®, iPad®, Android, Windows, and Mac PC's and Laptops and the web's most popular email platforms.

Identillect Technologies has a new service collaboration with the National Association of Professional Agents (NAPA), providing NAPA members access to the Company's set of compliance tools. This includes the Identillect Delivery Trust™ email encryption service. NAPA specializes in building custom company-sponsored E&O and benefit programs tailored to meet the unique requirements of a sponsoring company’s distribution force.

The design of these security solutions is to respond to agents need to successfully ensure or improve their HIPAA compliance. Delivery Trust™ is an email encryption solution. It is being deployed by small businesses and enterprises at a monthly subscription fee.

Last week, Identillect Technologies announced another month of positive growth for August 2017. The Company experienced subscriber growth over 6 percent for the month of August over the past 7 month average.

In addition, last week, Identillect Technologies announced its new partnership with CISOSHARE to provide their clients with Delivery Trust™.  Delivery Trust™ aligns with CISOSHARE’s mission to help companies build and maintain a wide-ranging cyber security management system from start to finish. This includes policy, processes, as well as people.  CISOSHARE services a broad assortment of organizations in the healthcare, government, financial, and cloud based sectors.

Identillect Technologies Corp. (IDTLF), closed Monday's trading session at $0.07615, down 9.45%, on 48,000 volume with 11 trades. The average volume for the last 60 days is 364,845 and the stock's 52-week low/high is $0.0546/$0.16.

Alliance BioEnergy Plus, Inc. (ALLM)

Stocks That Move reported earlier on Alliance BioEnergy Plus, Inc. (ALLM) and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Alliance BioEnergy Plus, Inc. centers on the commercialization and licensing of a patented cellulose conversion technology. The Company controls this technology through a master license agreement with the University of Central Florida. Alliance BioEnergy Plus’s subsidiaries concentrate on developing technologies in the renewable energy, bio-fuels, and new technologies sectors. Alliance BioEnergy Plus is based in West Palm Beach, Florida.

The Company operates various subsidiaries. AMG Energy Group, LLC owns 50 percent of Carbolosic, LLC (in a joint venture (JV) with Thor Renewable Energy Singapore) and exclusively the territories of North America and Africa. Carbolosic holds the exclusive international license for the patented CTS™ (Cellulose to Sugar) process, developed and owned by the University of Central Florida.

The CTS™ process converts cellulose into commercial grade sugars, fine chemicals, as well as other highly valuable products. Alliance BioEnergy Plus’s intention is to focus on the production of these commercial products through company-owned and licensed facilities.

Alliance’s commercial pilot/demonstration and research facility, Ek Laboratories, LLC, came online in early 2015. Under the direction of CTS™ inventor Dr. Richard Blair, the facility is running the CTS process, at a commercial scale, and is providing licensees with real time analytics.

The AMG Energy Group subsidiary was established to be the technology arm of the Company. AMG focuses on the licensing of Alliance BioEnergy Plus’s Intellectual Property (IP), engineering and construction of CTS plants, and developing technologies in the renewable energy, bio-fuels, and new technology sectors.

The CTS Cellulose Ethanol technology can produce a high quality, clean burning Ethanol from almost any plant material less costly, quicker, and without any hazardous inputs. Alliance BioEnergy Plus has completed the construction of its commercial scale CTS demonstration plant and research laboratories at its subsidiary Central Florida Institute of Science and Technology, Inc. (CFIST).

Alliance BioEnergy Plus has identified high growth potential in the biodegradable plastic market. This market, according to research, will reach $58-65 billion in 2022. It was 19.54 billion in 2016. The Company has the approval and acceptance of the United States Department of Agriculture (USDA) to purchase a closed bioethanol plant.

Alliance BioEnergy Plus has filed an 8K with the SEC (Securities and Exchange Commission) disclosing that its subsidiary Alliance Bio-Products, Inc. entered into a material definitive agreement to buy the closed ethanol facility in Indian River County, Florida. It tendered an initial deposit of $250,000.

The Company received approval from the United States Department of Agriculture (USDA) Office of Rural Development (USDA Rural Development) to move ahead with the purchase in early July. The approved purchase, at a price of $8M, includes the fully functional plant, 144-plus acres that the plant resides on, and all related equipment and vehicles.

Alliance BioEnergy Plus, Inc. (ALLM), closed Monday's trading session at $0.18, down 3.64%, on 61,542 volume with 54 trades. The average volume for the last 60 days is 84,626 and the stock's 52-week low/high is $0.11/$2.119.

Delta International Oil & Gas, Inc. (DLTZ)

Speculating Stocks, OTC Markets, and MarketWatch reported on Delta International Oil & Gas, Inc. (DLTZ), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Delta International Oil & Gas, Inc. is a global, independent oil and gas company specializing in energy. Until recently, the Company’s principal emphasis was on oil and gas exploration in northern Argentina by way of its subsidiary SAHF, LLC. This year, upon an evaluation of the U.S. domestic E&P market, it decided to focus its investments locally. The Company’s investment in MHD Technology Corp. helps extend its reach in the energy field. MHD Technology is a New York company that works to apply its patented technology in MagnetoHydroDynamics to water pipelines in the continental United States.  Delta International Oil & Gas is based in Scottsdale, Arizona. 

Delta is evaluating prospects for investments in fields other than oil and gas exploration and production. It earlier announced its acquisition of a 10 percent interest in MHD Technology Corp. via its wholly-owned subsidiary Neptune Industries LLC. 

MHD Technology is developing a unique water transportation and desalination technology. MHD's next steps are to perform a simulation of its product and then to make the first prototype. Delta's subsidiary, Neptune Industries, will initially be involved in both steps and also in some administrative role.  

As of March 31, 2016, Delta, via South American Hedge Fund LLC (SAHF), retained 18 percent of the total concession in the carryover mode (no cost obligations to SAHF) in the Tartagal and Morillo oil and gas concessions in Northern Argentina. Delta doesn’t operate the Tartagal and Morillo concession. It has a minority position in the JV. Furthermore, Delta holds a 30.6 percent interest in the Valle de Lerma concession in Northern Argentina. The JV partners are Grasta SA, PetroNEXUS, High Luck Group, and REMSA.

The properties presently held by SAHF are Tartagal Oriental, Morillo, and Valle de Lerma. SAHF is in the process of selling the Tartagal Oriental and Morillo properties. SAHF is not owned by Delta anymore, but as the sale of Tartagal Oriental and Morillo closes, Delta International Oil & Gas will receive 75 percent of the revenues produced by the transaction (including royalties on the production of the properties). Delta signed an agreement with High Luck for the sale of 18 percent of Tartagal and Morillo. Delta also signed and executed an agreement for the transfer of 100 percent of its interest in SAHF.

Delta International Oil & Gas announced this past August that it closed its first investment in Landmaster Partners, Inc. This investment was done in the form of an 18-month Note with a 9 percent interest and a carried interest in the first two wells.

The intention of the note is to fund the first two re-entry wells that Landmaster has proposed to drill in a Haskell County, Texas property. Landmaster Partners is a Texas-focused oil exploration and production enterprise.

Last month, Delta International Oil & Gas announced that it signed an asset purchase agreement for the acquisition of an oil property in Polk County, Texas from Crestmont Operating, LLC.

With this definitive agreement, Delta acquired a 4-well lease in Polk County, estimated to produce 15-20 barrels of oil per day once a workover is completed on one of the wells.

Delta International Oil & Gas, Inc. (DLTZ), closed Monday's trading session at $0.046, even for the day. The average volume for the last 60 days is 10,244 and the stock's 52-week low/high is $0.0127/$0.1598.

NEMUS Bioscience, Inc. (NMUS)

Zacks, InvestorsHub, MarketWatch, Bloomberg, OTC Markets, Barron’s, Stockhouse, and TradingView reported on NEMUS Bioscience, Inc. (NMUS), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

NEMUS Bioscience, Inc. is concentrating on the discovery, development, and commercialization of cannabinoid-based therapeutics for significant unmet medical needs in worldwide markets. A highly-qualified team of executives with decades of biopharmaceutical experience and substantial background in early-stage drug development leads the Company. A biopharmaceutical company, NEMUS’ vision is to provide physicians and patients the medical benefits of "condition-specific" cannabinoids to alleviate symptoms associated with a range of diseases. NEMUS Bioscience has its headquarters in Costa Mesa, California.

The Company centers on discovering, developing, as well as commercializing new chemical entities from a class of chemically diverse compounds - cannabinoids - designed to alleviate an array of diseases and symptoms via selectively targeting CB1 and CB2 receptors. NEMUS is building a proprietary product pipeline focusing on the range from extraction processes to molecular design and inventive methods of cannabinoid drug delivery to address medical needs in the multi-billion-dollar international market opportunities.

In 2015, NEMUS Bioscience signed a research agreement with the University of Mississippi (UM). The research agreement is to study and conduct research and development (R&D) on cannabidiol (CBD) containing formulations. NEMUS, using certain proprietary technology licensed from UM, is working to develop novel ways to deliver cannabinoid-based drugs for specific indications. Its aim is optimizing the clinical effects of such drugs, while limiting the potential adverse events. Its strategy will explore the use of natural and synthetic compounds, alone or in combination.

NEMUS Bioscience has completed the validation stage of testing of its cannabinoid-based therapy undergoing development for the treatment and management of glaucoma. The therapy, NB1111, is a proprietary prodrug version of tetrahydrocannabinol (THC), which has been shown to reduce intraocular pressure (IOP) in a rabbit glaucoma model. The compound has been in-licensed from the Company’s commercial and research partner, the University of Mississippi (UM).

In May 2017, NEMUS Bioscience announced that patents were granted in Canada and Hong Kong covering its proprietary prodrug of THC, THC-valine-hemisuccinate (THCVHS), and other amide-ester forms of cannabinoid-based molecules. The patents are licensed to Nemus Bioscience by the University of Mississippi (UM). They further broaden the potential commercial territories for THCVHS. The molecule has already received patent coverage in the U.S., Japan, the UK, the EU, and Australia. THCVHS is the active pharmaceutical ingredient (API) in Nemus Bioscience’s' glaucoma drug candidate NB1111.

NEMUS Bioscience, Inc. (NMUS), closed Monday's trading session at $0.275, up 6.36%, on 74,161 volume with 13 trades. The average volume for the last 60 days is 62,383 and the stock's 52-week low/high is $0.225/$1.80.


The QualityStocks
Company Corner


Blue Moon Zinc Corp. (TSX.V: MOON) (OTC: BMOOF)

The QualityStocks Daily Newsletter would like to spotlight Blue Moon Zinc Corp. (BMOOF). Today, Blue Moon Zinc Corp. closed trading at $0.0852, up 10.08%, on 74,161 volume with 13 trades. The stock’s average daily volume over the past 60 days is 62,383 and its 52-week low/high is $0.225/$1.80.

Blue Moon Zinc Corp. (TSX.V: MOON) (OTC: BMOOF), a mineral exploration company, is focused on developing its advanced-stage, wholly owned Blue Moon zinc project in central California. The project sits within Mariposa County, an area of active mines and exploration projects since it was part of the California gold rush era. Blue Moon's 525 acres of mineral rights are assigned to patented and unpatented claims accessible by a gravel road off a nearby highway with main utility lines nearby.

The Blue Moon deposit is one of many located in the Foothills Massive Sulphide Belt in the Sierra Nevada Mountains of California. The property has a long history of exploration and saw small-scale mining during World War II. The current project, to be mined by underground methods, contains an estimated 3.70 million tons with a grade of 8.33% zinc equivalent for approximately 377 million pounds of zinc in the indicated category and another 4.09 million tons with a grade of 7.84% zinc equivalence for approximately 395 pounds of zinc in the inferred category. Significant bi-products of copper, silver and gold are also indicated. The deposit is open at depth and along strike with a high likelihood of expansion.

Current spot prices for zinc is approximately $1.40 per pound, which increases the potential returns of the Blue Moon project.

The historical database shows extensive plans to put the Blue Moon project into production, including several scoping and optimization studies. Past environmental work performed, along with an historical permit and reclamation plan approved for certain underground development, highlights past local county support for the project. These historical studies and permits are expected to help fast track the project's progress as they form an excellent base for the upcoming Preliminary Economic Assessment and later feasibility study.

Among the significant historical studies conducted is a 1998 metallurgical report that shows recovery rates of 95 percent for zinc and lead, 93 percent for copper, 65 percent for silver and 70 percent for gold (http://nnw.fm/U1ckE). The report indicates that simple processing methods will produce premium concentrates with easy separation of the economic minerals.

Blue Moon CEO Patrick McGrath, who has 20 years of experience in financing and executive roles in the junior mining public sector, is joined by a management team with successful track records in leading and participating in significant mineral discoveries with development-stage mining companies. The Blue Moon team also includes a member who permitted and built the Soledad mine in southern California in 2016 and a member who re-started the Mesquite mine in southern California. Local knowledge and know-how is key. The company also plans to engage a recognized third-party engineering firm to prepare a preliminary economic assessment report, expected for release in the first quarter of 2018, to demonstrate the economic viability of the Blue Moon mineral resources. Disclaimer

Blue Moon Zinc Corp. Blog

Blue Moon Zinc Corp. News:

Blue Moon Provides Corporate Update

Savant Explorations Ltd. Changes Name to Blue Moon Zinc Corp. and Stock Symbol to "MOON"

Savant Explorations Ltd. Closes Oversubscribed $600,000 Financing; Grant of Stock Options

MGX Minerals Inc. (MGXMF)

The QualityStocks Daily Newsletter would like to spotlight MGX Minerals Inc. (MGXMF). Today, MGX Minerals Inc. closed trading at $0.6742, off by 3.69%, on 61,542 volume with 54 trades. The stock’s average daily volume over the past 60 days is 84,626 and its 52-week low/high is $0.11/$2.119.

MGX Minerals Inc. (CSE: XMG) (FKT: 1MG) (OTCQB: MGXMF) is a diversified Canadian resource company developing large-scale mineral portfolios in specific commodities and jurisdictions in North America. The company controls significant interest in lithium, magnesium and silicon assets that offer streamlined development timelines and low capital expenditures. MGX Minerals and its engineering partner have developed a patent-pending, low-energy design process to extract valuable minerals from the abundant, highly mineralized brine wastewater produced each year by oil and gas companies.

This proprietary, petrolithium process rapidly concentrates lithium and other minerals from brine in less than a day. That's a stunning advancement from the conventional method of extracting minerals from brine through an evaporation process that can take up to 18 months, requires hundreds of acres of land, and averages less than a 50 percent mineral recovery rate. Using this advanced water purification technology, MGX Minerals cleans the wastewater that accompanies petroleum as it's being pulled up to the surface. The company's petrolithium process eliminates the need to inject contaminated wastewater back into the ground, which prevents drinking water contamination and possible earthquakes.

In January 2017, MGX Minerals successfully recovered concentrated lithium from heavy oil evaporator blowdown wastewater using its rapid recovery process, an accomplishment independently confirmed by the Saskatchewan Research Council. In August 2017, the company also successfully processed wastewater and lithium brine from eight North American projects at its one-cubic-meter-per-hour processing plant, proving the technology is economically viable. Research group Global Water Intelligence expects the wastewater treatment industry to grow into a $45 billion market annually by 2025, which suggests there are ample revenue-generating opportunities for MGX Minerals technology.

Lithium, the "white gold" of the new energy economy, is the key to clean energy development as global demand for hybrid and electric vehicles, high-drain portable electronic devices, and large-scale energy storage systems ramps up. Grand View Research, Inc. reports that the global lithium-ion battery market is expected to reach $93.1 billion by 2025. Current market forces show a high demand for lithium and a low supply, which further supports the necessity of MGX Mineral's cleaner, faster method of extracting high-value minerals from brine wastewater.

MGX Minerals is led by a team of industry standout performers who have worked in the mining and technology industries for decades. The leadership team is joined by an array of top-notch technical partners with unmatched experience in the oil and gas sectors, environmental services industry, marketing and product development, along with applied research and commercial development of technologies. Disclaimer

MGX Minerals Inc. Blog

MGX Minerals Inc. News:

MGX Minerals Appoints Mining Executive Ian Graham as VP Operations

MGX Minerals Uplisted in United States to OTCQB Marketplace Under Symbol MGXMF

Hard-Rock Lithium Exposure for MGX Minerals

ChineseInvestors.com, Inc. (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com, Inc. (CIIX). Today, ChineseInvestors.com, Inc. closed trading at $0.59, up 25.53%, on 569,957 volume with 256 trades. The stock’s average daily volume over the past 60 days is 90,709 and its 52-week low/high is $0.33/$2.75.

ChineseInvestors.com, Inc. (OTCQB: CIIX) ("CIIX" or the "Company"), the premier financial information website for Chinese-speaking investors, today announces that it has appointed Skin Care Industry veteran and Shanghai beauty influencer, Fannie (Chun Fang) Tang as Marketing Director of its wholly-owned foreign enterprise, CBD Biotechnology Co., Ltd. effective immediately.

Founded in 1999, ChineseInvestors.com, Inc. (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world's first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer's disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX's cannabis-focused "Yelp"-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide. Disclaimer

ChineseInvestors.com, Inc. Blog

ChineseInvestors.com, Inc. News:

ChineseInvestors.com, Inc. Appoints Skin Care Industry Veteran and Shanghai Beauty Influencer, Fannie Tang, as Marketing Director of its Wholly-owned Foreign Enterprise, CBD Biotechnology Co., Ltd.

ChineseInvestors.com, Inc. Announces Paul Dickman's Return as its Chief Financial Officer

NetworkNewsWire Announces Publication on Cannabis Industry Forecasts and Public Companies Advancing in the Market

Patriot One Technologies, Inc. (TSX.V:PAT) (OTCQB:PTOTF)

The QualityStocks Daily Newsletter would like to spotlight Patriot One Technologies, Inc. (PTOTF). Today, Patriot One Technologies, Inc. closed trading at $0.66, up 13.79%, on 396,650 volume with 213 trades. The stock’s average daily volume over the past 60 days is 53,207, and its 52-week low/high is $0.4665/$1.49.

Patriot One Technologies Inc. (TSX VENTURE: PAT) (OTCQB: PTOTF) (FRANKFURT: 0PL) ("Patriot One" or the "Company"), is extremely pleased to announce that its award-winning PATSCAN CMR™ (Cognitive Microwave Radar) concealed weapons detection system has achieved Federal Communications Commission (FCC) Declaration of Conformity certification, a copy of which can be found here: https://fccid.io/2ALZTCMR.

Patriot One Technologies, Inc. (TSX.V: PAT) (OTCQB: PTOTF) is leveraging seven years of development to create powerful technologies that mitigate security risks by detecting concealed weapons via novel radar technology.

Developed through a NATO-funded project at McMaster University, Patriot One's disruptive NForce CMR1000 technology is the first cost-effective solution available for active shooter prevention, the need for which is evidenced by an increasing number of active shooter events in the United States and worldwide.

A recent study that surveyed data going back as far as 1966 demonstrates that there have been significantly more mass shootings in the U.S. than any other country for decades. Statistics for the 46-year period shows that even though America only holds 5% of the world's population, it took count of 31% of all public mass shootings. According to the FBI, there were an astounding 160 incidents from 2000 to 2013 that resulted in 486 people killed and 557 wounded. In years 2014 and 2015, there were nearly six times as many incidents compared to 2000 and 2001. The disturbing trend shows that there will be increasingly more incidents if better preventative measures aren't taken.

Patriot One's patent-pending solution to this alarming progression enables stand-off detection, even on moving targets, with a "cognitive" ability to learn and identify new threats once deployed. The product is not intended to threaten the constitutional rights of legal gun carriers, and it is also void of privacy and health concerns of traditional detection technologies, which require subject compliance, present false positives, and are often slow, inefficient and costly.

In contrast, Patriot One's technology is small in size and can be "covertly" placed in a doorway or hallway to prevent planned attacks in public places like schools, concerts, stadiums, banks, airports, offices, hospitals, shopping centers and other facilities for which there are concerns. With this method of deployment, there is no subject compliance requirement. In addition, because an image of the target is not generated, there are also no privacy concerns. Detection is real-time and entirely computer-based, which means there is no need for human operators to alert security. This eliminates the safety concerns of a would-be operator, reduces the expense of a human operator, and enables overall accuracy of 93%.

The technology is designed to identify if someone is carrying a gun, knife, suicide vest, etc., by analyzing metal content and relating it to a database of known weapon signatures. Patriot One believes the widespread use of this detection technology could act as an effective deterrent, thereby diminishing the epidemic phenomena of active shooters across the nation and around the world.

The company is guided by a team of experts in the areas of high-frequency electromagnetics, counter-terrorism, conflict resolution, government/corporate interface, sensor development, proactive security and business development. Senior Management has partnered with, among other affiliates, Ridge Global, which was founded by recently appointed advisory board member Tom Ridge, the first head of the Department of Homeland Security, first U.S. Secretary of Homeland Security, and 43rd governor of Pennsylvania.

Along with its partners, Patriot One is addressing global concerns of active shooting events and other violent terrorist attacks. The key is to short-circuit the event through effective prevention technologies and security protocols. Disclaimer

Patriot One Technologies, Inc. Company Blog

Patriot One Technologies, Inc. News:

Patriot One Receives FCC Approval for PATSCAN CMR Paving Way for Commercial Roll-Out

March Networks and Patriot One Announce Integrated Video and Covert Weapon Detection Solution

Patriot One to Present at Extraordinary Future 2017 Investment Conference

ORHub, Inc. (ORHB)

The QualityStocks Daily Newsletter would like to spotlight ORHub, Inc. (ORHB). Today, ORHub, Inc. closed trading at $0.545, off by 0.46%, on 26,300 volume with 15 trades. The stock’s average daily volume over the past 60 days is 66,853 and its 52-week low/high is $0.20/$2.09.

ORHub, Inc. (OTC: ORHB), an advanced medical software company focused on real-time case-based data analytics, today announces that the Company has successfully completed over 2,000 surgeries at a surgical institution in Southern California, revealing that it is running ahead of schedule as its national rollout strategy begins.

ORHub, Inc. (ORHB) is a cloud-based software platform designed to transform the business of surgery into a value-based model. The platform empowers care providers at every stage of the surgical process to collaborate, organize, deliver, measure, and reimburse in one intuitive, easy-to-use program. This significantly decreases cost and improves outcomes by eliminating inefficiencies, duplications of effort, and errors and omissions that result from siloed processes in outdated software and poor handoffs from one part of the care process to another.

The need for ORHub is clear. Health care costs are out of control at more than 17% of US GDP, which equates to over $3 trillion per year. With costs rising every year due to an aging population and increasingly expensive treatments, providers are under severe pressure to become more efficient and reduce costs. This is happening because payors are aggressively reducing reimbursements and finally moving away from fee-for-service and toward a performance-based reimbursement system referred to as value-based health care.

Accurately measuring the cost of treating a condition and relating that cost to the patient's outcome is at the heart of value-based health care. Institutions that have adopted this model have reaped savings of 20-40% on their overall cost of care. Unfortunately, today's siloed IT systems are fundamentally at odds with this process. Legacy health care solutions come from a fee-for-service world and have reinforced the problem and produced a system with erratic quality and unsustainable costs. Most health care applications today are incremental improvements on these existing systems or are simple digital implementations of antiquated pen-and-paper processes.

Providers wanting to practice value-based health care need value-based software. ORHub creates a value-based solution that will revolutionize surgical care delivery by tracking the cost of treating a condition from diagnosis to discharge, and tracking outcomes that resulted from that treatment.

In an industry where major IT rollouts traditionally cost millions of dollars and take an average of eighteen months, pilot installations of ORHub have been completed in less than a month. By avoiding integration with legacy systems completely through a radically comprehensive and collaborative approach, providers see results right away. This approach produces real-time metrics in a uniform manner at any institution, which makes it ideal for large providers looking to make improvements across the board at multiple facilities.

ORHub started as a pilot program developed in cooperation with a major Southern California hospital. It has since expanded operations into a second facility at the number two non-profit hospital system in the US. Three additional pilot programs are scheduled prior to a national launch. The company has raised more than $1.6 million as of January 2017.

The company is also a showcase member of the startup program at Microsoft, which has been a key partner by providing financial assistance, strategy, introductions to influencers and mentors, and access to its sales organization who see ORHub as an exciting partner to expand the utilization of Microsoft Surface devices and Azure Cloud. Microsoft is funding a major case study in partnership with Intel about the impact of ORHub on participating institutions to be concluded sometime in Q2 2017.

ORHub's leadership team is helmed by Colt Melby, who was appointed CEO in 2016 and has been crucial to developing and executing the company's business strategy. Mr. Melby's extensive business experience includes the NASDAQ uplisting of Smith and Wesson (now American Outdoor Brands), CUI Global Inc., and Quest Resource Holdings Corp. His wealth of information and relationships have been vital in helping the company go from concept to production in institutional medicine in less than a year.

Delivering surgical care to a single patient is a complex process that may take half a dozen companies and more than a dozen departments cooperating inside and outside the care facility. ORHub simplifies and streamlines this process by enabling vendors, providers, and surgeons to collaborate on providing care. Disclaimer

ORHub, Inc. Blog

ORHub, Inc. News:

ORHub, Inc. Completes over 2,000 Surgeries at Industry Leading Surgical Institution

ORHub, Inc. Completing 2-Year Financial Audit for Advancement to the OTCQB Market

ORHub (ORHB) Announces COO Leave of Absence


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



MarketClub Analysis
(ECYT) +157.45%


(NC) +66.58%


(ZAAP) +44.61%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251